ODONATE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,850 USD | -83.34% |
|
-83.34% | -81.00% |
| 2023 | North American Morning Briefing : Recession Threat Grows as Further Tightening Likely | DJ |
| 2023 | North American Morning Briefing : Stock Futures -2- | DJ |
| Sales 2019 | - | Sales 2020 | - | Capitalization | 740M 59.06B |
|---|---|---|---|---|---|
| Net income 2019 | -112M -8.94B | Net income 2020 | -126M -10.06B | EV / Sales 2019 | - |
| Net cash position 2019 | 178M 14.24B | Net cash position 2020 | 152M 12.13B | EV / Sales 2020 | - |
| P/E ratio 2019 * |
-
| P/E ratio 2020 |
-
| Employees | 145 |
| Yield 2019 * |
-
| Yield 2020 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -83.34% | ||
| 1 week | -83.34% | ||
| Current month | -83.34% | ||
| 1 month | -81.64% | ||
| 3 months | -82.73% | ||
| 6 months | -81.00% | ||
| Current year | -81.00% |
1 week
2 849.50
2 849.50
1 month
2 849.5018 810.00
Current year
2 849.5049 895.00
1 year
2 849.5049 895.00
3 years
2 849.5049 895.00
5 years
2 849.50464 999.00
10 years
2 849.50464 999.00
| Managers | Title | Age | Since |
|---|---|---|---|
Kevin Tang
CEO | Chief Executive Officer | 57 | 31/12/12 |
Michael Hearne
DFI | Director of Finance/CFO | 61 | 31/12/14 |
Ryan Cole
COO | Chief Operating Officer | - | 31/12/13 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kevin Tang
CEO | Chief Executive Officer | 57 | 31/12/12 |
Craig Johnson
BRD | Director/Board Member | 62 | 30/06/17 |
Aaron Davis
BRD | Director/Board Member | 45 | 30/11/16 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/05/24 | 2,850 | -83.34% | 2 |
Delayed Quote OTC Markets, May 09, 2024 at 09:30 pm
More quotes
Odonate, Inc., formerly Odonate Therapeutics, Inc., is a pharmaceutical company. The Company is focused on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. The Company is no longer in development of tesetax.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -81.00% | 8.09M | |
| +29.98% | 682B | |
| +32.29% | 586B | |
| -3.52% | 364B | |
| +18.59% | 327B | |
| +4.07% | 285B | |
| +16.30% | 240B | |
| +9.40% | 209B | |
| -9.16% | 203B | |
| +7.09% | 165B |
- Stock Market
- Equities
- ODT Stock
